Business context and reporting period
Ligand Pharmaceuticals Incorporated filed this Form 10-K for the fiscal year ended December 31, 2018. Ligand is a biopharmaceutical licensing and technology company; it earns primarily royalties, license and milestone payments, and Captisol material sales. Its partners generally fund development and commercialization. The portfolio included more than 200 partnered programs and agreements with over 110 companies.
Financial performance and position
Amounts are in U.S. dollars; financial figures below are in millions unless stated otherwise.
| Metric | FY 2018 | FY 2017 |
|---|---|---|
| Revenue | $251.5 | $141.1 |
| Operating income | $163.7 | $68.1 |
| Net income | $143.3 | $12.6 |
| Operating cash flow | $194.1 | $88.6 |
| Cash and cash equivalents | $117.2 | $20.6 |
| Short-term investments | $601.2 | $181.0 |
| Total assets | $1,260.8 | $671.0 |
- Revenue grew 78%; operating margin was approximately 65% and net margin approximately 57%.
- Revenue comprised royalties of $128.6, material sales of $29.1, and license fees, milestones and other revenue of $93.8. Major one-time license receipts included $47.0 from WuXi and $20.0 from Roivant.
- Promacta and Kyprolis generated $99.3 and $21.7 of royalties, respectively, under the 2018 accounting method. These two products represented the bulk of royalty income.
- Net income included a $50.2 gain related to Ligand’s Viking investment, including a substantial unrealized fair-value gain. Interest expense was $48.3, including $44.0 of non-cash debt discount accretion. The 17% effective tax rate was below 2017’s 78%.
- Quarterly data show Q4 revenue of $59.6 and a net loss of $42.5, versus annual net income of $143.3. The filing text provided here does not clearly isolate the specific drivers of the fourth-quarter loss.
- Year-end principal debt was $777.3: $27.3 of 2019 Notes and $750.0 of 2023 Notes. Notes payable, net of discounts and issuance costs, totaled $636.3. Cash plus short-term investments was approximately $718.4; working capital was $788.3.
- Capital structure included a $750.0 convertible-note issuance at 0.75% due 2023. Ligand repurchased $127.5 of shares during 2018. Cash dividends were not expected.
Material changes versus the prior comparable period
- Royalty revenue rose 45%, principally reflecting higher partner sales of Promacta and Kyprolis. Captisol sales increased 32%, partly due to customer purchase timing.
- License, milestone and other revenue increased 209%, driven mainly by the WuXi and Roivant payments. Operating expenses rose 20%, less than revenue growth.
- Ligand adopted ASC 606 in 2018, recognizing royalties in the quarter the underlying partner sales occur rather than one quarter later. Comparative prior-year figures were not restated: on the former ASC 605 basis, 2018 royalties would have been $121.0 rather than $128.6. Adoption also increased opening retained earnings by $25.6, net of tax.
- Ligand acquired Vernalis for approximately $43.0 in cash and paid $10.0 for economic rights to PTX-022. The 2018 financing and investment activity substantially increased cash and short-term investments, while the company also repaid or settled $217.7 principal of 2019 Notes.
Outlook, commentary, risks and contingencies
- Management expected cash, cash equivalents, short-term investments and operating cash flows to fund near-term operating and capital needs for at least 12 months. No quantified revenue or earnings guidance was provided.
- Management planned continued R&D, potential strategic acquisitions and investments, and share repurchases. It described CE-iohexol as preparing for a Canadian clinical-trial submission, with Phase 1 activity and data anticipated in 2019; timing and outcomes remain uncertain.
- Revenue is concentrated among a limited number of partners and products. The filing reports three partners each contributing at least 10% of revenue in 2018, with shares of 40%, 20% and 13%; the partner identities are not specified in that concentration disclosure.
- Captisol relies on a single supplier, Hovione, creating supply-interruption risk. Other principal risks include partner termination or underperformance, clinical and regulatory failure, generic competition and patent challenges, reimbursement pressures, and dependence on intellectual property.
- Convertible debt may require significant cash settlement and could dilute shareholders. The 2023 Notes had $750.0 principal outstanding; the 2019 Notes were due in 2019. Convertible-note transactions also generated significant non-cash interest and fair-value accounting effects.
- Two notable legal matters were a Teva patent dispute relating to Evomela/Captisol, with claim-construction proceedings scheduled for April 2019 and trial potentially beginning in January 2020, and investor litigation challenging a supplemental indenture. Ligand said it intended to defend both matters.
- Other unusual items included the Viking fair-value gain and ongoing remeasurement of acquisition-related contingent liabilities. The company disclosed no off-balance-sheet arrangements. The auditor issued unqualified opinions on the financial statements and internal controls.
Important facts for investors to verify
- How much of 2018’s royalty growth reflects underlying product sales versus ASC 606’s one-quarter timing change, and whether the partner-reported royalty estimates are subsequently revised.
- Current sales trends and competitive or patent developments for Promacta and Kyprolis, given their importance to royalties.
- Cash requirements, conversion and settlement terms, and potential dilution associated with the 2019 and 2023 Notes and related hedge and warrant transactions.
- Progress and regulatory outcomes for key partnered programs, including sparsentan, RVT-1502, and Captisol-enabled products; milestone and royalty potential is contingent on development and commercialization success.
- Resolution and possible financial effects of the Teva Evomela patent litigation and the supplemental-indenture lawsuit.